Focused on the development of regulatory T cell therapies
Sonoma is developing adoptive T reg cell therapies for autoimmune and inflammatory diseases. Using genome editing and target-specific cell therapy, Sonoma is focused on developing a best-in-class platform across the entire spectrum of T reg cell therapeutic capabilities. The company brings together expertise and proprietary methodologies for the discovery and development of disease-modifying and curative therapies.
